Target discovery

Nature Reviews Drug Discovery

Volumn 2, Issue 10, 2003, Pages 831-838

  Lindsay, Mark A ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CRE RECOMBINASE; DOUBLE STRANDED RNA; INSULIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; RIBONUCLEASE; SMALL INTERFERING RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; ATHEROSCLEROSIS; DISEASE MODEL; DRUG DESIGN; DRUG INDUSTRY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; GENOMICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; MEDICAL GENETICS; METHODOLOGY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PEPTIC ULCER; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; STROKE; TRANSGENIC ANIMAL; VALIDATION PROCESS;

EID: 0242363264     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1202     Document Type: Article

References (68)

1. Knowles, J. & Gromo, G. A guide to drug discovery: Target selection in drug discovery. Nature Rev. Drug Discov. 2, 63-69 (2003).
2. Grillone, L. R. & Lanz, R. Fomivirsen. Drugs Today 37, 245-255 (2001).
3. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
4. Kitano, H. Systems biology: a brief overview. Science 295, 1662-1664 (2002).
5. 2-agonists on airway tone and bronchial responsiveness. J. Allergy Clin. Immunol. 110, S304-S312 (2002).
6. Venkitaraman, A. R. A growing network of cancer-susceptibility genes. N. Engl. J. Med. 348, 1917-1919 (2003).
7. Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33, 238-244 (2003).
8. Doll, R., Peto, R., Wheatley, K., Gray, R. & Sutherland, I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 309, 901-911 (1994).
9. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
10. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
11. Weiner, H. L. & Selkoe, D. J. Inflammation and therapeutic vaccination in CNS diseases. Nature 420, 879-884 (2002).
12. Weisburger, J. H. Eat to live, not live to eat. Nutrition 16, 767-773(2000).
13. Horrobin, D. F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nature Rev. Drug Discov. 2, 151-154 (2003).
14. Gerhold, D. L., Jensen, R. V. & Gullans, S. R. Better therapeutics through microarrays. Nature Genet. 32, 547-551(2002).
15. Butte, A. The use and analysis of microarray data. Nature Rev. Drug Discov. 1, 951-960 (2002).
16. Zhang, M. Q. Extracting functional information from microarrays: a challenge for functional genomics. Proc. Natl Acad. Sci. USA 99, 12509-12511 (2002).
17. Slonim, D. K. From patterns to pathways: gene expression data analysis comes of age. Nature Genet. 32, 502-508(2002).
18. Seth, A. et al. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 23, 2043-2051(2003).
19. Phizicky, E., Bastiaens, P. I., Zhu, H., Snyder, M. & Fields, S. Protein analysis on a proteomic scale. Nature 422, 208-215(2003).
20. Aelbersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
21. Templin, M: F. et al. Protein microarray technology. Drug Discov. Today 7, 815-822 (2002).
22. Huber, L. A. Is proteomics heading in the wrong direction? Nature Rev. Mol. Cell Biol. 4, 74-80 (2003).
23. Young, A. B. Huntingtin in health and disease. J. Clin. Invest 111, 299-302 (2003).
24. Khurana, T. S. & Davies, K. E. Pharmacological strategies for muscular dystrophy Nature Rev. Drug Discov. 2, 379-390(2003).
25. Ratjen, F. & Doring, G. Cystic fibrosis. Lancet 361, 681-689(2003).
26. Goldstein, J. L. & Brown, M. S. Molecular medicine. The cholesterol quartet. Science 292, 1310-1312 (2001).
27. Tabor, H. K., Risch, N. J. & Myers, R. M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nature Rev. Genet. 3, 391-397(2002).
28. Romero, R., Kuivaniemi, H., Tromp, G. & Olson, J. The design, execution, and interpretation of genetic association studies to decipher complex diseases. Am. J. Obstet. Gynecol. 187, 1299-1312 (2002).
29. Sachidanandam, R. et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
30. Hirschhorn, J. N., Lohmueller, K., Byrne, E. & Hirschhom, K. A comprehensive review of genetic association studies, Genet. Med. 4, 45-61 (2002).
31. Lokey, R. S. Forward chemical genetics: progress and obstacles on the path to a now pharmacopoeia. Curr. Opin. Chem. Biol. 7, 91-96 (2003).
32. Lorens, J. B., Sousa, C., Bennett, M. K., Molineaux, S. M. & Payan, D. G. The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics. Curr. Opin. Biotechnol. 12, 613-621 (2001).
33. Hrabe de Angelis, M. H. et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nature Genet. 25, 444-447 (2000).
34. Nolan, P. M. et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nature Genet. 25, 440-443(2000).
35. Matthews, D. J. & Kopczynski, J. Using model-system genetics for drug-based target discovery. Drug Discov. Today 6, 141-149 (2001).
36. Walke, D. W. et al. In vivo drug target discovery: identifying the best targets from the genome. Curr. Opin. Biotechnol. 12, 626-631 (2001).
37. Pini, A. & Bracci, L. Phage display of antibody fragments. Curr. Protein Pept. Sci. 1, 155-169 (2000).
38. Devlin, J. J., Panganiban, L. C. & Devlin, P. E. Random peptide libraries: a source of specific protein binding molecules. Science 249, 404-406 (1990).
39. Burgstaller, P., Girod, A. & Blind, M. Aptamers as tools for target prioritization and lead identification. Drug Discov. Today 7, 1221-1228 (2002).
40. Braasch, D. A. & Corey, D. R. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 41, 4503-4510 (2002).
41. Petersen, M. & Wengel, J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 21, 74-81(2003).
42. Goodchild, J. Hammerhead ribozymes for target validation. Expert. Opin. Ther. Targets 6, 235-247 (2002).
43. Urnov, F. D. & Reber, E. J. Designed transcription factors as tools for therapeutics and functional genomics. Biochem. Pharmacol. 64, 919-923 (2002).
44. Dean, N. M. Functional genomics and target validation approaches using antisense oligonucleotide technology Curr. Opin. Biotechnol. 12, 622-625 (2001).
45. Shuey, D. J., McCallus, D. E. & Giordano, T. RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today 7, 1040-1046 (2002).
46. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
47. Yu, J. Y., DeRuiter, S. L. & Turner, D. L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 99, 6047-6052(2002).
48. Rubinson, D. A. et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genet. 33, 401-406 (2003).
49. Shen, C., Buck, A. K., Liu, X., Winkler, M. & Reske, S. N. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539, 111-114 (2003).
50. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635-637(2003).
51. Davis, M. E. Non-viral gene delivery systems. Curr. Opin. Biotechnol. 13, 128-131 (2002).
52. Merdan, T., Kopecek J. & Kissel, T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54, 715-758 (2002).
53. Wadia, J. S. & Dowdy, S. F. Protein transduction technology. Curr. Opin. Biotechnol, 13, 52-56 (2002).
54. Lindsay, M. A. Peptide-mediated cell delivery: application in protein target validation. Curr. Opin. Pharmacol. 2, 587-594 (2002).
55. Richard. J. P. et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278, 585-590(2003).
56. Green, I., Christison, R., Voyce, C. J., Bundell, K. R. & Lindsay, M. A. Protein transduction domains: are they delivering? Trends Pharmacol Sci. 24, 213-215 (2003).
57. Abbas-Terki, T., Blanco-Bose, W., Deglon, N., Pralong, W. & Aebischer, P. Lentiviral-mediated RNA interference. Hum. Gene Ther. 13, 2197-2201 (2002).
58. Barnett, B. G., Crews, C. J. & Douglas, J. T. Targeted adenoviral vectors. Biochim. Biophys. Acta 1575, 1-14 (2002).
59. Quinonez, R. & Sutton, R. E. Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 21, 937-951 (2002).
60. Burton, E. A., Fink, D. J. & Glorioso, J. C. Gene delivery using herpes simplex virus vectors. DNA Cell Biol. 21, 915-936(2002).
61. Gehl, J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177, 437-447 (2003).
62. Harris, S. Transgenic knockouts as part of high-throughput, evidence-based target selection and validation strategies. Drug Discov. Today 6, 628-636 (2001).
63. Abuin, A., Holt, K. H., Platt, K. A., Sands, A. T. & Zambrowicz, B. P. Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol. 20, 36-42 (2002).
64. Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug Discov. 2, 38-51 (2003).
65. Tornell, J. & Snaith, M. Transgenic systems in drug discovery: from target identification to humanized mice. Drug Discov. Today 7, 461-470 (2002).
66. Grimsditch, D. C. et al. C3H apoE(-/-) mice have less atherosclerosis than C57BL apoE(-/-) mice despite having a more atherogenic serum lipid profile. Atherosclerosis 151, 389-397 (2000).
67. Elbashir, S. M., Harborth, J., Weber, K. & Trischl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26, 199-213 (2002).
68. Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E. & Prydz, H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 30, 1757-1766 (2002).